Schär’s launch of 10 products represents the first steps toward FODMAPS becoming as everyday a message in the supermarket as gluten-free, according to a new report from New Nutrition Business, called FODMAPS: The next gluten-free?
Pundits are predicting that 2018 will be a growth year for FODMAPS, which has been bubbling under since its debut in Australia as a treatment for Irritable Bowel Syndrome (IBS).
“The launch illustrates the importance of the rapid emergence of an eating pattern which has every possibility of being as important as gluten-free,” said Julian Mellentin, director of New Nutrition Business. “That major companies such as Schär have chosen to step so early into FODMAPS is a sign of how seriously the trend can be taken. Companies will ignore it at their peril.”
A low-FODMAP or FODMAP-friendly diet is a solution for sufferers of the digestive complaint IBS which affects one in seven adults worldwide. FODMAPS are types of carbohydrate that can be particularly problematic for people with IBS, causing symptoms such as bloating or diarrhea.
The acronym FODMAPS comes from Fermentable Oligo-Di, Mono-saccharides And Polyols, which are types of short-chain carbohydrates found in a variety of foods. Onions, garlic, wheat and apples are among foods that can cause problems for people with IBS.
Pioneered by Monash University in Australia, FODMAPS is backed by a growing body of scientific studies and the concept has been gaining acceptance among dietitians and gastroenterologists over the last few years. A low-FODMAP diet is widely considered to be a front-line treatment for IBS.
Two certifying bodies (including Monash University) provide testing and certification for products. The Schär products are certified low-FODMAP by Monash University.
FODMAPS is attracting increasing consumer interest as well. As the report shows, online media and consumer attention is growing in markets as diverse as Spain and Finland.
“Powered by the huge Digestive Wellness trend—which has been the motive force behind plant milks, gluten-free and others—FODMAPS has potential to gain followers beyond the 10-15% of people who have IBS, just as the gluten-free market has grown to be far bigger than the tiny percentage of the population diagnosed with celiac disease,” said Mr. Mellentin.
“This trend is unlike many others in that it is an opportunity for established companies who are science-driven as well as for start-ups,” he added. “Nestle, Kellogg, Baker’s Delight (a mass-market bakery chain in Australia), Fazer (the biggest bakery in the Nordic countries) have all launched FODMAP-friendly products or re-labeled existing products as FODMAP-friendly. The entry of Schär, a reputable gluten-free giant, into FODMAPS underscores the opportunity.”
“The emerging market for products positioned as low-FODMAP or FODMAP-friendly has the potential to be as big as the gluten-free market,” he concluded.